ORASURE TECHNOLOGIES INC

OraSure Technologies develops and manufactures diagnostic and specimen collection devices focused on infectious disease testing and genomic sample collection. The company's core product portfolio includes rapid diagnostic tests for HIV, hepatitis C, syphilis, and Ebola, along with at-home and self-test variants. It also produces the InteliSwab line of COVID-19 rapid tests and the Intercept drug testing system. Beyond infectious disease, OraSure manufactures collection devices for genomic analysis under the Oragene and ORAcollect brands, as well as microbiome collection products through its OMNIgene line for DNA and RNA extraction from saliva, stool, and urine samples.

The company operates across two primary markets: clinical diagnostics and research specimen collection. Its diagnostic products serve clinical laboratories, hospitals, and public health organizations, while its collection devices target pharmaceutical, biotech, genomic research, and microbiome profiling markets. OraSure distributes its products through direct sales channels and distributors across North America, Europe, Africa, and other international markets.

Headquartered in Bethlehem, Pennsylvania, OraSure is incorporated in Delaware and listed on Nasdaq. The company maintains manufacturing and distribution capabilities to serve global clinical and research markets, with an estimated market capitalization of approximately $200 million.